Business
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
MIAMI, October 31, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. ("Akeso," HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland (Washington D.C
About this update from Akeso, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":292,"url":"https://media.zenfs.com/en/business-wire.com/0200f57a16b4e4076ccf2371916169b5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FqqfB6y64HpOe7OFHmn9eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0200f57a16b4e4076ccf2371916169b5","width":480,"height":292}},"lazy":false},{"type":"text","content":"Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"MIAMI, October 31, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. ("Akeso," HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland (Washington D.C. metro area) on Friday, November 7, 2025 at 11:30am ET.","length":613,"tagName":"p"},{"type":"text","content":"HARMONi-A evaluated ivonescimab combined with platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI) against placebo plus platinum-doublet chemotherapy. This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials. HARMONi-A was the first Phase III study conducted with ivonescimab and now represents the first statistically significant overall survival (OS) benefit achieved by an ivonescimab regimen over a standard of care regimen.","length":730,"tagName":"p"},{"type":"text","content":"HARMONi-A was a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso. Via the results of HARMONi-A, this setting w...